A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Long-Term Safety Study of MK0928 in the Treatment of Elderly Outpatients With Primary Insomnia
Latest Information Update: 05 May 2022
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational
- Sponsors Lundbeck A/S; Merck & Co
Most Recent Events
- 01 Feb 2010 New trial record